Pierre Fabre Laboratories collaborate with Vernalis

The French biotech company combines its experience in innovation, development, manufacturing, and commercialisation in oncology with the expertise of Vernalis in drug discovery. Vernalis contribute to the collaboration expertise in fragment and structure-based methods to identify small molecules that modulate their activity. The company, with research based in Cambridge UK, develops lead compounds and drug candidates against targets in oncology, neurodegeneration, anti-infectives and inflammation. The scientists integrate structural biology, biophysics, assay technology and molecular modelling with synthetic organic and medicinal chemistry expertise to identify pre-clinical candidates against multiple oncology targets. Further development and commercialisation will be performed by Pierre Fabre Laboratories, which fund the research of Vernalis.

Last year Pierre Fabre Laboratories posted €2.7bn in revenues. Most of their products are manufactured in France (90%). Its main R&D efforts are focused on targeted therapies, about 80% to oncology in 2022.